

January 31, 2020

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sirs,

**Sub: Unaudited Financial Results for the quarter ended December 31, 2019**

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended December 31, 2019 which were approved by the Board of Directors of the Company, at its meeting held on January 31, 2020 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 12:00 noon and concluded at 3.00 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

  
Rajesh Shirambekar  
Head – Legal & Company Secretary



Encl: As above

# BSR & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited Review report on unaudited Quarterly Standalone Financial Results and standalone year-to-date of RPG Life Sciences Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

### The Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 31 December 2019 and the year to date results for the period from 1 April 2019 to 31 December 2019 ('the Statement')
2. This Statement, which is the responsibility of the Company's management and which is approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP  
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Himanshu Chapsey  
Partner

Membership No: 105731

UDIN: 20105731AAAAAD6085

Place: Mumbai  
Date: 31 January 2020

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019						
(Rs. in Lakhs)						
Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	9,437	9,849	9,097	28,690	26,136	33,016
2 Other Income	4	15	2	35	38	80
3 Total Income	9,441	9,864	9,099	28,725	26,174	33,096
4 Expenses						
(a) Cost of Materials Consumed	2,273	1,746	1,459	5,696	4,164	5,117
(b) Purchases of Stock-in-Trade	1,849	1,951	1,132	4,934	3,304	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(932)	(436)	336	(906)	1,212	1,371
(d) Employee Benefits Expense	2,417	2,493	2,394	7,222	7,002	8,993
(e) Finance Costs	36	36	99	145	308	399
(f) Depreciation and Amortisation Expense	416	416	386	1,224	1,138	1,532
(g) Other Expenses	2,341	2,454	2,568	7,079	7,753	9,663
Total Expenses	8,400	8,660	8,374	25,394	24,881	31,591
5 Profit before tax	1,041	1,204	725	3,331	1,293	1,505
6 Income tax expenses						
a. Current Tax	327	321	120	948	266	284
b. Deferred Tax	(77)	(94)	77	(220)	100	140
7 Profit for the period	791	977	528	2,603	927	1,081
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(110)	(110)	(6)	(30)	(18)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	3	2	8	6	14
Other Comprehensive Income Net of Tax	(8)	(7)	(4)	(22)	(12)	(27)
9 Total Comprehensive Income for the period	783	970	524	2,581	915	1,054
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						14,727
12 Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	4.78	5.91	3.19	15.74	5.61	6.54
(b) Diluted	4.78	5.91	3.19	15.74	5.61	6.54

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2020. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and nine months ended December 31, 2019.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using the modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact on the financial results.



For RPG Life Sciences Limited

*(Signature)*

Yugal Sikri  
 Managing Director  
 Mumbai, January 31, 2020